Shorter disease duration in important for tocilizumab to achieve Boolean
Shorter disease duration in important for tocilizumab to achieve Boolean
复制标题
较短的病程对于托珠单抗实现布尔值非常重要
DOI：
10.1007/s10165-012-0822-7
复制
发表时间：
2013
期刊：
影响因子：
2.2
通讯作者：
Hashiramoto A.
中科院分区：
文献类型：
--
作者：
Kawasaki Y;Hashiramoto A;Okano T;Sakai Y;Yamane T;Shiozawa K;Shiozawa S;Hashiramoto A.
目的确定诱导类风湿性关节炎（RA）到疾病缓解托珠单抗（TCZ）的最佳条件，我们分析了TCZ治疗进行了我们facility.MethodThe研究组包括116例RA患者开始TCZ治疗在科比大学医院和甲南加古川医院。结果TCZ治疗24周后，25.9%的患者达到布尔定义的疾病缓解（布尔缓解）。DAS 28-ESR 4从0周的5.25 ± 1.15改善至24周的2.75 ± 1.34（均数± SD，P <0.0001），并且57.8%的患者实现DAS 28缓解。对疾病持续时间和缓解之间关系的分析表明，该比值比在3.0年时达到峰值。单变量分析显示布尔缓解与基线ESR水平、Steinbrocker分类和分期以及患者疾病活动性总体评估（PGA）相关。因此，我们根据3.0年峰值对患者组进行了分类和比较。我们发现显着差异Steinbrocker的类和stag.ConclusionTCZ治疗导致布尔疾病缓解是最佳的，当开始不到3.0年后，疾病发作。
ObjectiveTo determine the optimal conditions for inducing rheumatoid arthritis (RA) into disease remission by tocilizumab (TCZ), we analyzed the TCZ therapy carried out in our facility.MethodThe study group comprised 116 patients with RA who started TCZ therapy at Kobe University Hospital and Konan-Kakogawa Hospital. The clinical response to TCZ was evaluated by the 2011 Boolean definition and the disease activity score of 28 joints erythrocyte sedimentation rate 4 (DAS28-ESR4).ResultsAfter 24 weeks of TCZ therapy, 25.9 % of the patients achieved a Boolean-defined disease remission (Boolean remission). DAS28-ESR4 was improved from 5.25 ± 1.15 at week 0 to 2.75 ± 1.34 at week 24 (mean ± SD,P <0.0001), and 57.8 % patients achieved DAS28 remission. Analysis of the relationship between disease duration and remission showed that this odds ratio peaked at 3.0 years. Univariate analyses showed that Boolean remission was associated with baseline ESR levels, Steinbrocker’s class and stage, and patient global assessment of disease activity (PGA). Accordingly, we categorized and compared the patient groups referring to the 3.0-year peak. We found significant differences in Steinbrocker’s class and stage.ConclusionTCZ therapy leading to Boolean disease remission is optimal when initiated less than 3.0 years after disease onset.